Friday, November 15, 2024
Home Blog Page 3223

Livespo Navax – World’s first spore probiotics in nasal spray form triumphs in ongoing clinical trials tackling influenza-related respiratory inflammation

Livespo Navax – World’s first spore probiotics in nasal spray form triumphs in ongoing clinical trials tackling influenza-related respiratory inflammation

HANOI, VIETNAM – Media OutReach – 30 November 2023 – A recent publication in the Scientific Reports – Nature journal has once again highlighted the clinical trials of LiveSpo Navax spore probiotic spray. These trials focus on its effectiveness against respiratory tract inflammation from the influenza virus. This news marks a significant milestone for the Vietnamese medical sector, especially in setting a trend in global research and application of spore probiotics for respiratory well-being.

Caption

Using a nasal spray with Bacillus probiotics in treating influenza patients has significantly reduced the total treatment time by up to 60 per cent (from five days for the control group to just two days for the spore probiotics spray group).

Additionally, it increased treatment efficacy by 58 per cent, aiding in the complete recovery from symptoms such as runny nose, fever, sneezing, cough, rapid heartbeat, and rapid breathing. The decline in clinical symptoms corresponds with a drop in both viral and bacterial counts, notably decreasing by approximately 400 and 1,000 times on the second treatment day compared to the initial day of hospitalisation.

The clinical trials confirm that the nasal spray containing Bacillus probiotics reduces treatment duration, lowering the chances of bacterial infection or severe respiratory tract complications. This not only helps cut treatment costs but also reduces antibiotic consumption for infections, fostering improved patient health. This positive signal is crucial for the medical community as it contributes to easing the burden on hospitals during disease outbreaks.

Furthermore, the clinical trials indicate that the Bacillus probiotics, when formulated as a spray, offer superior effectiveness through interaction with the mucosal immune system of the nasal cavity. This means that the spore probiotics nasal spray not only supports the treatment of influenza-infected patients but also aids in treating respiratory tract inflammation caused by other viruses such as RSV, adenovirus, rhinovirus, coronavirus, etc. Regular use of Bacillus probiotics spray proves beneficial in enhancing the respiratory barrier, thereby boosting the effectiveness of virus-prevention vaccines.

Probiotics, also known as a type of medicinal probiotics, serve as an effective solution in alleviating symptoms of respiratory diseases. In a previous study published in the Scientific Reports – Nature journal in July 2022, LiveSpo Navax supported the treatment of respiratory syncytial virus (RSV) in children. It significantly reduced the treatment time by more than one day and lowered the RSV concentration by over 600 times, surpassing the effectiveness of using physiological saline. This scientific research ranked among the top 100 downloaded microbiology articles in 2022 in the Nature Journal, demonstrating the widespread interest from scientists and readers worldwide and contributing significant values to the community.

The two internationally validated clinical studies have confirmed that the LiveSpo Navax nasal spray, containing Bacillus probiotics, has demonstrated no side effects, guaranteeing complete safety for children. All patients using LiveSpo Navax in conjunction with standard treatment medications showed no signs of local bacterial infection or any digestive issues like vomiting, diarrhoea, or other abnormal symptoms. Therefore, in the future, this product will be fully suitable for inclusion in treatment plans for patients infected with respiratory viruses or bacteria.

Dr. Nguyen Hoa Anh, Director of the Spore Probiotics Research Center shared: “We are proud to offer an effective support solution for patients with respiratory infections caused by viruses, bacteria, or acute inflammation. Moving forward, we will continue to research, develop, and bring the LiveSpo Navax product to consumers in Viet Nam and globally.”

With groundbreaking technology in spore probiotics – medicinal probiotics, LiveSpo Pharma aims to build a future free of antibiotics for everyone. Dang Quoc Hung, CEO of LiveSpo Pharma, stated: “At LiveSpo, we always strive to deliver the best products to our customers and the community. With the expertise of our scientific team, who have achieved notable research milestones in microbiology domestically and internationally, we are confident in developing and manufacturing effective and convenient spore probiotic products without side effects. This effort contributes to reducing antibiotic use and minimising antibiotic resistance in Viet Nam and the world. This is also LiveSpo’s mission for development.”

As confirmed by the two successful publications in the prestigious Scientific Reports – Nature journal, LiveSpo has asserted its breakthrough in the products resulting from the company’s extensive research and development efforts. LiveSpo takes pride in introducing Viet Nam’s spore probiotics technology to the markets of developed countries which spearhead global medical advancements. This groundwork sets the stage for the future growth of Vietnamese enterprises, emphasising the expansion into global markets and the international promotion of Vietnamese brands and products.

With a focus on product development, LiveSpo aims to create value for the community. The company’s successful development of the Bacillus probiotics spray, which effectively aids respiratory disease treatment and minimises the risk of severe inflammation and prolonged antibiotic use, is helping pave the way toward a future less reliant on antibiotics.

With its nature as a type of medical probiotic, LiveSpo products will help strengthen the natural immune barrier for the body when used over an extended period, thereby contributing to a community immune system if widely applied. This serves as a natural shield, protecting the community from diseases caused by viruses and bacteria.

Hashtag: #Livespo

The issuer is solely responsible for the content of this announcement.

About LiveSpo Pharma

LiveSpo is an R&D, manufacturing, and distribution brand of Spobiotics (probiotics in spore form) for digestive and respiratory health, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for “A Future Without Antibiotics”.

Hotline: 1800.088808

Website:

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

JinkoSolar to participate at COP28 United Nations climate conference

0

SHANGRAO, China, Nov. 30, 2023 /PRNewswire/ — JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced its participation at the COP28 United Nations climate change conference taking place in Dubai from November 30th to December 12th, underlining its leadership role in the solar energy sector and its commitment to addressing the challenges posed by global warming on a global scale.

This year’s COP28 motto "Partnership Promotes Progress", could not be more accurate. "Collaborative action is urgently needed to deliver an equitable energy transition. COP28 provides an excellent forum for real progress to be made towards climate action," stated Dany Qian, Vice President of Jinkosolar. She added, "Increasing global temperatures and environmental disasters show that we are already behind schedule. Any extra barriers to halt the progress doesn’t make sense. Every decision we make and action we take must be for the benefit of everyone on earth. "

As a full participant in the efforts to combat global warming, the Company will have a presence at the main conference and deliver a keynote speech titled ‘Solar is all, solar is for all’ in a series of key side events, engaging with all stakeholders to provide concrete actions for a just, equitable and affordable energy transition for all.

Jinkosolar is committed to accelerating transitioning to a world powered by more sustainable energy. Through its innovative technologies, extensive experience and a proven deliverable strategy, the Company is helping to make solar the answer to climate change.

As the world’s first solar company joining RE100 and EP100, Jinkosolar has committed to power 100% of its own business activities along its entire value chain with renewable energy by 2028.

About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world. JinkoSolar distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, Netherlands, Poland, Austria, Switzerland, Greece and other countries and regions.

JinkoSolar had 14 productions facilities globally, 24 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, the United States, Mexico, Brazil, Chile, Australia, Canada, Malaysia, the United Arab Emirates, Denmark, Indonesia, Nigeria and Saudi Arabia, and global sales teams in China, the United States, Canada, Brazil, Chile, Mexico, Italy, Germany, Turkey, Spain, Japan, the United Arab Emirates, Netherlands, Vietnam and India, as of September 30, 2023.

To find out more, please see: www.jinkosolar.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company’s operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
Ms. Stella Wang
JinkoSolar Holding Co., Ltd.
Tel: +86 21-5180-8777 ext.7806
Email: [email protected]  

Source : JinkoSolar to participate at COP28 United Nations climate conference

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

CABIO unveils NeoHMOs™ series at FIE 2023, targeting growing global demand for infant formula

0

FRANKFURT, Germany, Nov. 30, 2023 /PRNewswire/ — Fi Europe & Hi 2023 (FIE 2023), the annual European trade show for natural and healthy food and beverage ingredients, is being held in Frankfurt between November 28 and 30, 2023. Over the past 26 years, cumulative visitor count of the prestigious Fi Europe has surpassed 500,000 person/times. As a trusted provider of premium functional ingredients and innovative solutions catering to global customers, CABIO has always participated actively in this industry event to share our cutting-edge research and innovation achievements with worldwide consumers and industry peers.

This year, CABIO unveiled an exciting new product range, NeoHMOs™, at the FIE 2023. Our team’s successful development and production of various physiologically active human milk oligosaccharides (HMOs) caters to the ever-increasing consumer demand for natural and high-quality products. By employing synthetic biology technology, we have implemented a rational design and control process for HMOs, effectively reducing greenhouse gas emissions and energy consumption during production, and ensuring an eco-friendly manufacturing process. Moving forward, CABIO will remain committed to the research and production of HMOs, aiming to diversify their applications in the end market and provide a wider range of healthy choices for individuals across different age groups, including infants and adults.

As a core supplier in the global infant formula supply chain, CABIO is committed to upholding its heartwarming corporate philosophy that "behind every can of formula lies a baby", a value that has been cherished from the very beginning of our journey. We consistently maintain world-class standards in food safety and supply chain management, enabling us to provide high-quality functional nutritional products and diversified solutions to our customers in China and beyond.

At the FIE 2023, CABIO unveiled a wide range of products — arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc. as well as the NeoHMOs™ family, including 2′-Fucosyllactose (2′-FL), 3-Fucosyllactose (3′-FL), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LNnT), 3′-sialic lactose (3′-SL), and 6′-sialic lactose (6′-SL).

With an unwavering commitment to the brand philosophy that "biotechnology nourishes life", CABIO strives to deliver premium products and innovative solutions to customers in the fields of human nutrition, animal nutrition, cosmetics, and personal care. Our vision is to become a global leader in biotechnology, empowering and enriching lives through nutrition and health.

About Us

Established in September 2004, CABIO Biotech (Wuhan) Co., Ltd. ("CABIO" for short) (SSES: 688089) is a high-tech company founded on biotechnology.

Since initial public offering, CABIO has actively embraced the field of synthetic biology, having established dedicated laboratories and initiated an array of forward-thinking and market-driven research projects. With our synthetic biology platform as the foundation, we have proactively expanded our product portfolio and industry presence, driving the development of new products and fostering the growth of our business. Our commitment lies in leveraging biotechnology to empower life nutrition and health.

www.cabio.com 

Source : CABIO unveils NeoHMOs™ series at FIE 2023, targeting growing global demand for infant formula

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

IFS Cloud November Release reinforces AI capabilities across automation and optimization with IFS.ai

0

Further focus on ESG capabilities to accelerate time to value across business operations.

LONDON, Nov. 30, 2023 /PRNewswire/ — IFS, the global cloud enterprise software company, today announced the general availability of the second of its twice-yearly IFS Cloud releases for 2023. The release is centered on capabilities that will help customers to increase productivity across their business and leverage digital technology to build agility and operational excellence.  

The content of this November release is a continuation of IFS’ goal to help customers in its core industries to build their composable, intelligent autonomous enterprise.

From this release onwards, the company’s recently launched AI architecture IFS.ai‘s capabilities will be directly woven into all of IFS’s products and industry specific capabilities. This makes AI widely available across customers’ organizations, enabling them to simulate, optimize, and automate industry-specific business processes and increase productivity of their people, assets and services across their entire business operations.    

Enterprises are building business resilience to be able to respond quickly, effectively and in a sustainable way to changing macro-economic conditions. Achieving this for the longer term requires them to build agility and adaptability to mitigate risks, creating a bigger dependency on technology innovation. Those companies who have already invested in digitalization will be able to leverage AI faster and manage their operational performance, as well as increase productivity.

To this end, the November IFS Cloud release continues to focus on three strategic business themes:

Optimize People, Assets and Services Connect Global Operations Achieve ESG Goals Profitably

Optimizing People, Assets and Services:

IFS Cloud uses AI, ML, IoT and automation to streamline processes related to people, assets, and services and improve data quality and compliance.

Maximize capacity utilization by combining cross business insights and intelligent automation. (Manufacturing Scheduling & Optimization, ERP) Improve yield and throughput, reduce costs, and enhance production quality (Intelligent Automation in Manufacturing ERP) Boost order fulfilment, enhance productivity and improve customer service levels. (Supply Chain, ERP) Avoid maintenance procedure delays and minimize IT administration. (Aviation Maintenance) Maximize crew efficiency and reduce costs with higher first-time-fix rates. (Planning & Forecasting in Service Management)

Connect Global Operations:

IFS Cloud breaks down data and other operational silos, aligning and connecting people to identify risks and opportunities. The latest enhancements continue to target unwanted complexity, reduce downtime, and positively impact customer services. Advanced management capabilities include:

Combine critical business data and transaction updates to optimize offshore maintenance operations between shore and offshore assets. (EAM) Experience efficient and reliable service delivery with process automation along the entire financial value chain. (Service Management) Reduce costs and complexity and experience fast, efficient document signing with electronic signatures through Adobe integration. (Asset Management)

Achieve ESG Goals Profitably:

As customers and consumers become more demanding of a company’s ESG stance, a clear strategy and ability to deliver results will create long-term value. IFS Cloud is designed to help manage and achieve ESG goals, profitably and transparently. The latest update allows industries to leverage data to measure progress against commitments, demonstrate accountability, reuse components, reduce production costs and increase revenue.

Quickly access ESG-focused insights across energy consumption, materials used and DEI for more informed decision-making. (Lobbies in IFS Cloud) Easily and accurately track progress against Scope 1 and 2 sustainability goals. (IFS Cloud Emissions Tracker) Reuse components for re-manufacturing and reduce production costs. (Supply Chain, ERP)

Christian Pedersen, Chief Product Officer, IFS, said: "Accelerating digital transformation remains a top priority for our customers as they continue to depend on technology to build predictability in performance and resilience in their business. With this latest release of IFS Cloud, we have stayed true to our product vision to enable customers to adopt our innovation out of the box." Pedersen added: "This includes our commitment to providing a product that stays evergreen. Delivering a composable option that provides a clear path to always being up to date with the latest digital and AI innovation is central to that."  He concluded: "IFS.ai capabilities already exist in IFS Cloud, and we are continuing investment into this area. Our aim with AI is to make organizational-wide impact for all our customers across all their users."

About IFS

IFS develops and delivers cloud enterprise software for companies around the world who manufacture and distribute goods, build and maintain assets, and manage service-focused operations. Within our single platform, our industry specific products are innately connected to a single data model and use embedded digital innovation so that our customers can be their best when it really matters to their customers—at the Moment of Service™. The industry expertise of our people and of our growing ecosystem, together with a commitment to deliver value at every single step, has made IFS a recognized leader and the most recommended supplier in our sector. Our team of over 6,000 employees every day live our values of agility, trustworthiness and collaboration in how we support our 6,500+ customers. Learn more about how our enterprise software solutions can help your business today at ifs.com.

CONTACT:

IFS Press Contacts:

MEA& APJ: Adam Gillbe
Corporate Communications
Email: [email protected]
Phone: +44 7775 114 856
USA: Mairi Morgan

Corporate Communications
Email: [email protected]
Phone: +1 520 396 2155

The following files are available for download:

https://news.cision.com/ifs/i/ifs-cloud-november-release-image,c3244635

IFS Cloud November Release Image

 

Source : IFS Cloud November Release reinforces AI capabilities across automation and optimization with IFS.ai

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

The Best Class 4 Laser Therapy Machine Takes Center Stage at The 55th Dusseldorf International Hospital and Medical Equipment Exhibition in 2023

0
The Best Class 4 Laser Therapy Machine stood out as the undisputed leader at MEDICA 2023, securing global collaborations. A number of clients lauded its unprecedented performance, even making on-the-spot purchases. The Laser Therapy System continued to push the boundaries of medical laser technology and undoubtedly reshaped the landscape of physiotherapy, providing both clinicians and patients with a state-of-the-art solution.

DUSSELDORF, Germany, Nov. 30, 2023 /PRNewswire/ — Rhein Laser Technologies Ltd., a prominent manufacturer specializing in innovative medical lasers for aesthetic and physiotherapy markets with operations in Wuhan and Dusseldorf, has garnered widespread acclaim and attention from industry professionals at the exhibition in Germany. This innovative showcase includes Smart/Smart Ice laser therapy system, PowerCure/PowerCure Pro handheld home laser device, and SWAVE-200 electromagnetic shock wave therapeutic apparatus.


The Best Class 4 Laser Therapy Machine stood out as the undisputed leader at MEDICA 2023, securing global collaborations. A number of clients lauded its unprecedented performance, even making on-the-spot purchases. The Laser Therapy System continued to push the boundaries of medical laser technology and undoubtedly reshaped the landscape of physiotherapy, providing both clinicians and patients with a state-of-the-art solution.

In the realm of pain relief, the Smart/Smart Ice laser therapy system caters to the diverse needs of those enduring discomfort. With its innovative use of four wavelengths (635nm/810nm/915nm/980nm), the device penetrates up to 15 cm into subcutaneous tissue. It boasts a higher power range of 30-60W. The top-selling Smart Ice Laser Therapy System was widely embraced at this medical expo. Numerous attendees eagerly sought to explore and try the product, resulting in a flood of positive reviews.

At the exhibition, the PowerCure/PowerCure Pro handheld laser device stands out as a preferred Low-level Laser Therapy (LLLT) solution. With its compact design, the product has garnered significant favor from attendees. Emphasizing both portability and safety, the device utilizes 808nm and 650nm low-level diode lasers with a power range of up to 1060mW/1300mW. PowerCure/PowerCure Pro laser enables customers to easily self-administer treatments at home.

Furthermore, a multitude of attendees sought information about the SWAVE-200 at the exhibition. Having personally experienced the shock wave treatment, many expressed satisfaction, noting the absence of discomfort during the process. Surprisingly, this brief therapy significantly alleviated their longstanding pain issues. It effectively treats tendinopathy across the musculoskeletal system. The Shockwave therapeutic apparatus delivers effective relief within a mere 10 minutes of therapy. Moreover, the SWAVE-200 achieves an impressive 10 million shots.

According to Dr. Yang Lin, the founder of Rheinlaser, numerous attendees have expressed satisfaction with our products and shown a strong desire to make purchases. Many dealers are eagerly anticipating the presence of Rheinlaser at The 56th Dusseldorf International Hospital and Medical Equipment Exhibition in 2024, hoping that we will continue to bring innovative physiotherapy equipment and technology. As the exhibition comes to a close and Christmas approaches, Rheinlaser is gearing up to roll out exciting promotions for buyers worldwide. Visit the website for the latest updates.

For more information about the Smart Physiotherapy Systems, visit: https://smartlasertherapy.com

Media Contact: [email protected]

Source : The Best Class 4 Laser Therapy Machine Takes Center Stage at The 55th Dusseldorf International Hospital and Medical Equipment Exhibition in 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

UroFiber SuperPulsed Thulium Fiber Laser System Officially Debuts at MEDICA 2023

0
UroFiber SuperPulsed Thulium Fiber Laser System shines at MEDICA 2023, commanding global attention and fostering collaborative partnerships. Client acclaim echoed through the exhibition as they hailed UroFiber as the frontrunner, setting new standards in urological innovation. Trust in Rhein Laser, as we illuminate the path to advanced medical excellence through groundbreaking technology.

DUSSELDORF, Germany, Nov. 30, 2023 /PRNewswire/ — UroFiber SuperPulsed Thulium Fiber Laser System, developed by Rhein Laser Technologies Ltd., a pioneer in medical laser technology, made its first appearance at the esteemed MEDICA 2023 in Germany. This groundbreaking system sets a new standard for urological procedures as the world’s first 1940nm 150W SuperPulsed Thulium Fiber Laser (TFL) system for perfectly treating both stone lithotripsy and BPH enucleation. With unprecedented power and precision, UroFiber offers enhanced patient outcomes and marks a momentous milestone for advancing medical innovations.


UroFiber SuperPulsed Thulium Fiber Laser System shines at MEDICA 2023, commanding global attention and fostering collaborative partnerships. Client acclaim echoed through the exhibition as they hailed UroFiber as the frontrunner, setting new standards in urological innovation. Trust in Rhein Laser, as we illuminate the path to advanced medical excellence through groundbreaking technology.

Rhein Laser, a trailblazer in laser equipment manufacturing, brings unparalleled precision to industries worldwide. An impressive array of studies has validated the clinical efficacy of SuperPulsed Thulium Fiber Laser System in terms of tissue ablation, coagulation and hemostasis. These scientific evidences underscore Rhein Laser’s commitment to innovation rooted in rigorous research, providing healthcare professionals with a cutting-edge tool backed by robust scientific validation.

The UroFiber SuperPulsed Thulium Fiber Laser System showcased at MEDICA heralds a paradigm shift in medical surgery. Compared with conventional Ho: YAG, UroFiber Laser reduces dusting time in half, fragmenting stones relentlessly with virtually no retropulsion. Besides, it can precisely cut through soft tissue and achieve state-of-the-art prostate enucleation with visibly improved hemostasis. These features position UroFiber as a transformative force in the medical industry, with the potential to improve patient outcomes and streamline healthcare processes.

Rhein Laser’s presence at MEDICA 2023 reaffirms the soaring success of UroFiber in the international market. With tremendous global acclaim, UroFiber has garnered substantial international recognition and forged successful collaborations with global clients. This underlines Rhein Laser’s prowess in delivering innovative solutions and its ability to establish impactful partnerships across the globe.   

"We are thrilled to debut UroFiber at MEDICA 2023, offering medical professionals with an all-in-one solution for stone lithotripsy and BPH enucleation. We are confident that this revolutionary technology will not only elevate the standards of urological care but also pave the way for further advancements in laser-assisted surgical procedures," stated Dr. Lin Yang, CEO of Rhein Laser. "An increasing number of global clients eagerly anticipate witnessing our expanding range of products at MEDICA 2024. This undoubtedly reflects UroFiber’s enormous market prospects and cements its position as a frontrunner in the global medical technology landscape."

For more information about the UroFiber laser system, visit: www.UroFiber.com.

Media Contact:
[email protected] 

Source : UroFiber SuperPulsed Thulium Fiber Laser System Officially Debuts at MEDICA 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement

0
Dr. Kamil Tamiola the CEO of Peptone Ltd and Prof. Andrea Alimonti, MD, Incoming Director, and Professor of Molecular Oncology at IOR as seen in The Institute of Oncology Research (IOR) in Bellinzona, Switzerland.

Collaboration focused on novel target discovery in prostate cancer

LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ — Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology Research (IOR) today announced the commencement of a collaborative sponsored research agreement in prostate cancer. The collaboration will focus on the identification and progression of novel targets in oncology using translational models to develop innovative medicines for patients suffering from prostate cancer.


Dr. Kamil Tamiola the CEO of Peptone Ltd and Prof. Andrea Alimonti, MD, Incoming Director, and Professor of Molecular Oncology at IOR as seen in The Institute of Oncology Research (IOR) in Bellinzona, Switzerland.

"A collaboration with IOR combines Peptone’s unique expertise targeting disordered proteins with the power of generative machine learning, unique structural insights into disordered targets and patient insights about cancer born out of seminal work from Professor Alimonti’s group in Bellinzona," said Kamil Tamiola, PhD, CEO of Peptone. "Our collaboration is an excellent example of efficient technology transfer process and a burgeoning research and biotech ecosystem in Ticino, Switzerland."

Peptone is applying advanced biophysics atomic-level experimental approaches, including a novel ultra-low latency hydrogen-deuterium exchange mass spectrometry (HDX-MS), supercomputing and generative AI to interrogate and drug intrinsically disordered proteins (IDPs). IDPs are proteins that play a significant role in health and disease but because they lack a fixed structure, have been intractable or undruggable with conventional drug discovery approaches.

"Prostate cancer remains a highly prevalent disease with significant unmet clinical needs," said Professor Andrea Alimonti, MD, Incoming Director, and Professor of Molecular Oncology at IOR. "We are delighted to partner with Peptone on this research collaboration focused on novel target discovery in prostate cancer. Recent findings from my team demonstrate that advanced prostate cancer is regulated by several intrinsically disordered proteins, many of which can also control the tumor immune response. Targeting these proteins is a promising approach to this challenging disease." 

About Peptone
Peptone is a translational biophysics company focused on the discovery of novel therapeutics against diseases driven by intrinsically disordered proteins. IDPs are proteins without a fixed structure that play a significant role in health and disease. For more information about Peptone, visit peptone.io.

About IOR Bellinzona
The Institute of Oncology Research, established in 2003 in Bellinzona (Switzerland), is affiliated with the Università della Svizzera Italiana (USI). It hosts researchers from all over the world performing basic and translational research in oncology with a particular focus on cancer biology, genomics, molecular oncology and experimental therapeutics. The IOR is located in a brand-new high-tech research building that hosts more than 20 different research groups, with state-of-the-art labs and facilities. Together with the Institute for Research in Biomedicine (IRB), the IOR is a member of the Bellinzona Institutes of Science (Bios⁺), a recently established non-profit association aiming to promote, support and coordinate scientific research and teaching activities of its members.

Photo – https://mma.prnasia.com/media2/2288796/Peptone_CEO_Kamil_Tamiola_and_Prof_Andrea_Alimonti.jpg?p=medium600
Logo – https://mma.prnasia.com/media2/2223699/peptone_Logo.jpg?p=medium600

Source : Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Shanghai Electric's Efforts Included in 2023 ESG Excellent Cases of Chinese Public Companies

0

SHANGHAI, Nov. 30, 2023 /PRNewswire/ — Shanghai Electric (SEHK:2727, SSE:601727) was honored at the Chinese Listed Companies Sustainable Development Conference for its remarkable performance in Environmental, Social, and Governance (ESG). Included in the "2023 ESG Excellent Cases of Chinese Public Companies", the company’s progressive strategies and unique insights have significantly contributed to the transformation of the ESG landscape in China. The annual event, run by the China Association for Public Companies (CAPCO), acknowledges listed Chinese companies that have made considerable progress in areas such as climate impact, social responsibility, and corporate governance.

https://static.prnasia.com/pro/fec/jwplayer-7.12.1/jwplayer.js jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”   jwplayer(‘myplayer1’).setup({file: ‘https://mma.prnasia.com/media2/2289584/1.mp4’, image: ‘https://mma.prnasia.com/media2/2289584/1.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’});

This year, CAPCO received 451 ESG cases, doubling the amount from the previous year. Companies were evaluated based on their efforts in comprehensive ESG practices, with the emphasis on their actions to minimize carbon footprints and aid societal development.

Over the past few years, Shanghai Electric has been bolstering its ESG management and strategy, developing solutions that pave the way for China’s transition to new energy and empower the country to move towards a zero-carbon future. Driven by a vision to catalyze innovation in renewable and green energy while elevating global living standards, Shanghai Electric leverages its decades of expertise in energy and equipment manufacturing to offer a wide range of solutions that optimize the efficiency of energy generation, power transmission and distribution, railway infrastructure, and smart buildings.

On the environmental front, Shanghai Electric is leading the way in energy recycling innovation, creating systems that can handle flue gas, water, and solid waste treatment while significantly reducing carbon emissions. Holding environmental responsibility at its core, the Company is guided by green principles to enhance its production and operations while acknowledging its crucial role in environmental protection, embracing the climate and pollution challenges as a roadmap for business transformation, and setting clear goals for both short-term and long-term actions to promote sustainability.

Strategically integrating wind, solar, storage, and hydrogen energy, Shanghai Electric has synergized the advantages of traditional and renewable energy sources to develop a new generation of power systems characterized by low costs, low carbon emissions, and high performance. Shanghai Electric expands business alliances as it seeks to establish an industry eco-system, sharpening its competitive edge by focusing on R&D in key industries, which allows the Company to achieve remarkable outcomes in product innovation, project development, and talent cultivation in recent years.

Shanghai Electric is also committed to compliance with laws and regulations, with a strong emphasis on improving operational transparency. The Company strengthened its corporate governance by enhancing its internal compliance, establishing clear and effective communication channels, and safeguarding shareholder rights.

Now, Shanghai Electric has been included in the Hang Seng Sustainable Development Series Index, with its ESG rating upgraded to "A" by MSCI. Building upon its strategy designed to facilitate China’s dual-carbon goal of carbon peak and carbon neutrality, Shanghai Electric has further advanced its pledges for decarbonization by releasing Shanghai Electric’s Dual-Carbon Action Plan this year.

Source : Shanghai Electric's Efforts Included in 2023 ESG Excellent Cases of Chinese Public Companies

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network